Mersana’s innovative platforms have enabled us to build a pipeline for both Mersana and our collaborators. Our ADCs in preclinical studies and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need.
We believe our platforms create an opportunity for ADCs with improved safety and efficacy relative to those developed using first-generation technology.

Platform	ADC Program	Target	Indication	Preclinical	P1 Dose Escalation	P1 Dose Expansion
G1
Dolasynthen	Emi-Le (XMT-1660)	B7-H4	Multiple Solid Tumors
G2
Immunosynthen	XMT-2056*	Novel HER2 Epitope	Multiple Solid Tumors
Collaborations
Collaborations:
Dolasynthen		Undisclosed	Undisclosed
Immunosynthen		Undisclosed	Undisclosed

Platform	ADC Program	Target	Indication	Phase
Dolasynthen	Emi-Le (XMT-1660)	B7-H4	Multiple Solid Tumors	P1 Dose Expansion
Immunosynthen	XMT-2056*	Novel HER2 Epitope	Multiple Solid Tumors	P1 Dose Escalation
Collaborators:
Dolasynthen		Undisclosed	Undisclosed	Preclinical
Immunosynthen		Undisclosed	Undisclosed	Preclinical

^*XMT-2056 is wholly owned by Mersana, with GSK having an exclusive global license option to co-develop and commercialize the candidate.